Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 75.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 949 shares of the company’s stock after buying an additional 407 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Medpace were worth $317,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after purchasing an additional 50,312 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Medpace by 38.3% in the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock valued at $182,692,000 after purchasing an additional 122,800 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after purchasing an additional 109,886 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in shares of Medpace by 55.1% in the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock valued at $166,343,000 after purchasing an additional 143,481 shares in the last quarter. Finally, American Capital Management Inc. lifted its stake in shares of Medpace by 2.6% during the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock valued at $127,060,000 after buying an additional 9,592 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. UBS Group downgraded shares of Medpace from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $420.00 to $350.00 in a research note on Friday, September 27th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and reduced their price objective for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, Robert W. Baird upped their price objective on shares of Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a research note on Monday, November 25th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $380.56.

Medpace Stock Performance

Medpace stock opened at $331.00 on Thursday. The firm’s 50-day moving average is $339.54 and its 200-day moving average is $366.89. Medpace Holdings, Inc. has a 1 year low of $277.72 and a 1 year high of $459.77. The company has a market cap of $10.29 billion, a P/E ratio of 28.98, a PEG ratio of 1.89 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. During the same period last year, the firm posted $2.22 EPS. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.